Natera (NTRA) Expected to Announce Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is anticipated to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Natera to announce earnings of ($0.4939) per share and revenue of $661.2430 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Natera Stock Up 1.0%

Shares of NASDAQ:NTRA opened at $270.36 on Tuesday. The business’s 50 day moving average is $248.11 and its 200 day moving average is $222.36. The stock has a market cap of $38.72 billion, a P/E ratio of -165.87 and a beta of 1.51. Natera has a 52-week low of $133.01 and a 52-week high of $288.04.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NTRA shares. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada assumed coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Barclays decreased their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Wednesday, June 24th. William Blair began coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, UBS Group set a $260.00 target price on shares of Natera in a report on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $267.83.

Insider Buying and Selling

In related news, insider John Fesko sold 931 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $236,539.17. Following the completion of the transaction, the insider owned 184,069 shares in the company, valued at $46,766,410.83. The trade was a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 1,863 shares of Natera stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.38, for a total transaction of $464,594.94. Following the completion of the transaction, the chief financial officer directly owned 52,432 shares in the company, valued at $13,075,492.16. This represents a 3.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 173,469 shares of company stock worth $39,310,838 in the last three months. 5.05% of the stock is owned by company insiders.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC raised its position in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares during the period. Focus Partners Wealth grew its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Natera in the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera in the 2nd quarter valued at $558,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.